Proteins & Biologics

3Bio Biologics — Proteins & Biologics

Where Europe’s scientific rigor meets the global CDMO Network.
Where protein programs scale smarter, faster, and with unmatched optionality.

A New Standard in Global Protein Development

Protein therapeutics remain the backbone of modern biopharmaceutical innovation. Yet the true challenge today is not simply expressing a protein — it is expressing it with precision, with manufacturability in mind, and with a clear path through scale-up, regulatory scrutiny, and final drug product readiness. 3Bio Biologics was created to meet this challenge at a level no single-site CDMO can match.

The CDMO Network is Built for Innovation, 3Bio Biologics banner

As the European Regional Hub of the CDMO Network, 3Bio integrates expertise, infrastructure, analytic depth, and global optionality into a unified ecosystem. Unlike traditional CDMOs, we draw on a collaborative network spanning North America, Europe, and Asia, allowing us to support nearly any protein program, any modality, and any complexity — from early discovery to clinical and commercial scale.

We build on the strengths of partners while expanding far beyond their capabilities, creating the most comprehensive protein development ecosystem in Europe.

Microbial Proteins — High-Yield, High-Performance, Highly Engineered

Microbial expression continues to be the most powerful tool for producing enzymes, growth factors, industrial biocatalysts, and next-generation protein modalities. But microbial systems demand mastery — fermentation, refolding, solubility engineering, impurities, endotoxin control, and downstream strategies define success or failure.

At 3Bio, we combine:

  • High-density fermentation
  • E. coli, Pichia pastoris, and advanced yeast platforms
  • Automated process optimization
  • Predictive modeling and real-time analytics
  • Deep experience in refolding and purification of complex proteins

Our microbial programs incorporate Quality by Design (QbD) from day zero, using modeling frameworks inspired by leading European engineering research to build robustness long before scale-up begins. Through the CDMO Network, we can seamlessly route your program to the right facility for 2 L, 200 L, 2,000 L or full commercial production.

Microbial protein development at 3Bio is not a service — it is an engineered strategy for success.

Mammalian Proteins — Precision, Scalability, and Clinical Reliability

Therapeutic antibodies, fusion proteins, cytokines, and complex glycoproteins require mammalian expression systems that are stable, scalable, and reproducible.

3Bio Biologics integrates:

  • CHO and HEK293 stable cell line development
  • Fed-batch and perfusion systems
  • Glycoengineering strategies
  • High-throughput clone screening
  • cGMP manufacturing across multiple global sites
  • Full DS → DP integration with aseptic fill-finish

The CDMO Network eliminates the bottleneck of single-site mammalian capacity. We select the optimal facility in our ecosystem based on:

  • modality
  • regulatory pathway
  • scale
  • timeline demands
  • specialized analytics
  • cost-efficiency

This ensures that mammalian protein programs do not stall — they advance.

Bioconjugated Biotherapeutics — ADCs, Fusion Proteins, and Hybrid Modalities

3Bio supports conjugated biologics through partners specializing in:

  • Antibody-drug conjugates (ADCs)
  • Linker-payload optimization
  • Fusion proteins
  • Half-life extension strategies
  • Precision bioconjugation chemistries
  • Protein + small molecule hybrid therapeutics

By combining protein manufacturing hubs with conjugation experts in the Network, we create modular, scalable, and regulator-ready development pathways.

This is where biologics meet chemistry — and where complexity becomes competitive advantage.

End-to-End Process Development — From Molecule to Manufacturable Reality

Protein development is not linear. It’s iterative, data-driven, and requires constant alignment between upstream, downstream, analytics, and regulatory strategy.

3Bio offers:

  • Upstream process development (USP)
  • DSP purification strategy
  • Formulation development
  • Stability mapping
  • Scale-up modeling
  • Process characterization & validation
  • Tech transfer across global sites

We apply QbD principles across the entire arc, with real-time monitoring, PAT integration, and the beginnings of digital twin modeling through Icarus-X — the future CDMO Network OS.

This is where 3Bio leaps ahead of other European CDMOs.

Analytics & QC — Depth, Precision, and Global Standardization

Borrowing from the rigorous QC model used by the best, and expanding beyond it, 3Bio provides:

  • Physicochemical characterization
  • Identity, purity, and structural confirmation
  • Potency and bioassays
  • Stability-indicating methods
  • Aggregation and impurity profiling
  • Host cell protein/DNA quantification
  • Full IND/IMPD release testing
  • Method development & validation

As part of the CDMO Network, 3Bio has access to multiple QC hubs worldwide — ensuring no program is delayed by capacity bottlenecks or instrumentation backlogs.

This QC scalability is a major competitive edge.

Global Fill-Finish Integration — Protein Programs Completed Under One Roof

Through the CDMO Network, 3Bio offers integrated fill-finish pathways including:

  • Aseptic vial filling
  • Pre-filled syringe formats
  • Dual-chamber cartridge systems
  • Lyophilization cycle development + GMP lyophilization
  • Visual inspection
  • Sterility testing
  • Packaging & labeling
  • Qualified Person release (EU)

Protein programs that begin with 3Bio can be carried all the way through DP manufacturing without disruption, delay, or cross-CDMO confusion.

This is where Europe gains a true multi-modal biologics hub.

Regulatory Alignment from Day One

3Bio supports:

  • IND/CTA/IMPD authoring
  • comparability & bridging studies
  • CMC strategy
  • risk assessments
  • validation planning
  • global regulatory navigation

With CDMO Network partners across the US, EU, and Asia, we strategically choose where each step is most efficient — accelerating approvals and reducing regulatory friction.

Digital Bioprocessing — The Next Evolution of Protein Manufacturing

This is the category other CDMOs cannot touch.

3Bio is the only European CDMO hub backed by the development of:

  • Model Predictive Control (MPC) systems
  • Digital twins for fermentation and cell culture
  • Automated QbD modeling
  • Bioprocess simulation platforms
  • Icarus-X — the CDMO Network OS (2027 launch)

This gives our clients a scientific and operational advantage:

  • Fewer failed batches
  • Smarter scale-up
  • Data-rich optimization
  • Predictive manufacturability
  • Faster regulatory approval

This is the future of biologics — and 3Bio sits at the center of it.

The Power of the CDMO Network — 3Bio’s Ultimate Advantage

3Bio Biologics has something no standalone CDMO can claim:

Global optionality + regional specialization + neutral governance + continuous capacity.

Through the CDMO Network, we offer:

  • EU, US, and Asia manufacturing routes
  • rapid capacity matching
  • modality-specific expertise
  • multi-CDMO strategy architecture
  • early-stage → commercial continuity
  • unbiased partner selection

Clients don’t get a facility — they get an ecosystem.

This dramatically reduces program risk:

  • no single bottleneck
  • no capacity surprises
  • no dead ends
  • no unnecessary tech transfers
  • no dependence on a single site’s limitations

3Bio is Europe’s gateway to the world’s most adaptive biomanufacturing infrastructure.

With You All the Way — Europe’s Hub in a Global Biologics Future

We are building the infrastructure for tomorrows life-transforming therapies.
3Bio builds on that spirit — and elevates it.

We are:

  • the European engine of the CDMO Network
  • the most comprehensive protein development hub on the continent
  • a connector of geographies, capabilities, and scientific excellence
  • a partner from concept to clinic to commercialization

Our mission is simple:

To create a smarter, more connected, and more resilient future for biologics manufacturing — where companies scale not just faster, but better.